We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AURA icon
101
Aura Biosciences
AURA
$826M
$656K 0.11%
73,663
-129,574
-64% -$1.11M
AKRO
102
CALL
DELISTED
Akero Therapeutics
AKRO
$646K 0.11%
+22,500
New +$587K
NETD
103
DELISTED
Nabors Energy Transition Corp II
NETD
$639K 0.1%
+59,900
New +$636K
OPCH icon
104
Option Care Health
OPCH
$3.56B
$626K 0.1%
20,000
+8,000
+67% +$246K
JANX icon
105
Janux Therapeutics
JANX
$966M
$591K 0.1%
13,000
+5,109
+65% +$222K
KURA icon
106
Kura Oncology
KURA
$847M
$586K 0.1%
+30,000
New +$608K
TMTC
107
DELISTED
TMT Acquisition Corp Ordinary Shares
TMTC
$562K 0.09%
50,000
– –
KYMR icon
108
Kymera Therapeutics
KYMR
$8.92B
$561K 0.09%
11,856
-38,770
-77% -$1.71M
INDV icon
109
Indivior Pharmaceuticals
INDV
$4.58B
$527K 0.09%
54,057
-15,950
-23% -$187K
MASI
110
DELISTED
Masimo
MASI
$519K 0.08%
3,894
+3,856
+10,147% +$447K
LXEO icon
111
Lexeo Therapeutics
LXEO
$377M
$517K 0.08%
57,166
+55,866
+4,297% +$666K
TH icon
112
Target Hospitality
TH
$1.65B
$511K 0.08%
65,741
-47,885
-42% -$448K
TSHA icon
113
Taysha Gene Therapies
TSHA
$1.88B
$505K 0.08%
251,400
+600
+0.2% +$1.32K
SLNO
114
DELISTED
Soleno Therapeutics
SLNO
$505K 0.08%
10,000
-29,929
-75% -$1.43M
ARVN icon
115
Arvinas
ARVN
$575M
$502K 0.08%
20,400
-12,000
-37% -$313K
USFR icon
116
WisdomTree Floating Rate Treasury Fund
USFR
$18.4B
$502K 0.08%
10,000
-43,000
-81% -$2.16M
APLS
117
DELISTED
Apellis Pharmaceuticals
APLS
$498K 0.08%
17,252
-3,398
-16% -$126K
VTGN icon
118
VistaGen Therapeutics
VTGN
$12.7M
$491K 0.08%
+163,078
New +$556K
EWTX icon
119
Edgewise Therapeutics
EWTX
$4.68B
$485K 0.08%
18,178
-418,430
-96% -$8.32M
BPMC
120
DELISTED
Blueprint Medicines
BPMC
$472K 0.08%
+5,100
New +$507K
VKTX icon
121
Viking Therapeutics
VKTX
$3.99B
$450K 0.07%
7,100
-84,127
-92% -$4.94M
TXMD icon
122
TherapeuticsMD
TXMD
$24.1M
$448K 0.07%
270,160
– –
PHGE icon
123
BiomX
PHGE
$1.82M
$441K 0.07%
+22,774
New +$826K
AQN icon
124
Algonquin Power & Utilities
AQN
$4.42B
$436K 0.07%
80,000
+65,000
+433% +$369K
MOVE icon
125
Corvex Inc
MOVE
$360M
$416K 0.07%
10,500
-2,238
-18% -$86.5K
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.